Shaan C. Gandhi is Vice President and Head of Strategic Partnerships for Pfizer Ignite. Prior to joining Pfizer, Shaan served as Director at Northpond Ventures, where he led the firm's biotechnologies team. Prior to that role he was Principal at the Longwood Fund, where he co-founded and served as President of Pyxis Oncology (NASDAQ: PYXS), an antibody-drug conjugate and monoclonal antibody oncology company.
In his prior investor roles, Shaan served on the boards of Candel Therapeutics (NASDAQ: CADL), DICE Therapeutics (NASDAQ: DICE), Vigil Neuroscience (NASDAQ: VIGL) and on multiple private boards, including Aro Biotherapeutics, CAMP4 Therapeutics, Garuda Therapeutics, Kyverna Therapeutics, Mestag Therapeutics, Opna Bio, Parthenon Therapeutics, Totus Medicines, Transition Bio, and Triumvira Immunologics. He started his career as an attending hospitalist at Massachusetts General Hospital, where he also did his residency in internal medicine.
He holds an MD from Harvard Medical School; an MBA from Harvard Business School, where he was a Baker Scholar; a DPhil in medical oncology from the University of Oxford, where he was a Rhodes Scholar; and a BS with honors in biochemistry from Case Western Reserve University.